MCID: LRY011
MIFTS: 24

Larynx Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Larynx Verrucous Carcinoma

MalaCards integrated aliases for Larynx Verrucous Carcinoma:

Name: Larynx Verrucous Carcinoma 11 14
Verrucous Carcinoma of the Larynx 11
Laryngeal Verrucous Carcinoma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:3752
NCIt 49 C8188
UMLS 71 C0280328

Summaries for Larynx Verrucous Carcinoma

MalaCards based summary: Larynx Verrucous Carcinoma, also known as verrucous carcinoma of the larynx, is related to verrucous carcinoma and larynx cancer, and has symptoms including pain and hoarseness. An important gene associated with Larynx Verrucous Carcinoma is TP53 (Tumor Protein P53). The drugs Carboplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lung and breast.

Related Diseases for Larynx Verrucous Carcinoma

Diseases related to Larynx Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 verrucous carcinoma 11.0
2 larynx cancer 10.5
3 laryngeal benign neoplasm 10.5
4 keratoacanthoma 10.5
5 squamous cell carcinoma 10.3
6 alcohol dependence 10.1
7 spastic paraplegia, ataxia, and mental retardation 10.1
8 common wart 10.1
9 head and neck cancer 10.1
10 alcohol use disorder 10.1
11 keratosis 10.1
12 papilloma 10.1
13 laryngeal squamous cell carcinoma 10.1
14 leukoplakia 10.1

Graphical network of the top 20 diseases related to Larynx Verrucous Carcinoma:



Diseases related to Larynx Verrucous Carcinoma

Symptoms & Phenotypes for Larynx Verrucous Carcinoma

UMLS symptoms related to Larynx Verrucous Carcinoma:


pain; hoarseness

Drugs & Therapeutics for Larynx Verrucous Carcinoma

Drugs for Larynx Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
2
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
4
Fluorouracil Approved Phase 3 51-21-8 3385
5 Antimitotic Agents Phase 3
6 Tubulin Modulators Phase 3
7 Immunoglobulins, Intravenous Phase 3
8 Immunoglobulins Phase 3
9 Antibodies, Monoclonal Phase 3
10 Antibodies Phase 3
11 Antineoplastic Agents, Immunological Phase 3
12 Immunologic Factors Phase 3
13 Angiogenesis Inhibitors Phase 3
14 Mitogens Phase 3
15 Antimetabolites Phase 3
16 Immunosuppressive Agents Phase 3
17 Endothelial Growth Factors Phase 3
18 Immunoglobulin G Phase 3
19
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
20 Raspberry Approved Phase 1, Phase 2
21
Cetuximab Approved Phase 2 205923-56-4
22
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
23
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
24
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
25
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
26
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
27
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
28
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
29
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
30
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
31
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
32
Trioxsalen Approved Phase 2 3902-71-4 5585
33
Saracatinib Investigational Phase 2 379231-04-6 10302451
34
Cediranib Investigational Phase 2 288383-20-0 9933475
35
Maleic acid Experimental, Investigational Phase 2 110-16-7, 110-17-8 444266 444972
36
MK-1775 Investigational Phase 2 955365-80-7 24856436
37
Dihematoporphyrin ether Investigational Phase 2 97067-70-4
38
Diethyl ether Experimental Phase 2 60-29-7 3283
39 Antiviral Agents Phase 2
40 Anti-Infective Agents Phase 2
41 Expectorants Phase 2
42 Antidotes Phase 2
43 N-monoacetylcystine Phase 2
44 Respiratory System Agents Phase 2
45 Antioxidants Phase 2
46 Protective Agents Phase 2
47 Protein Kinase Inhibitors Phase 2
48 Lactams Phase 2
49 Epothilones Phase 2
50 Epothilone B Phase 2 4456137

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
2 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
3 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
4 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
5 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
6 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
7 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
8 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
9 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
10 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
11 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
12 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Completed NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
13 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
14 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
15 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
16 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
17 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
18 A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma Completed NCT02007200 Phase 2 Soy Isoflavones
19 A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy Completed NCT01256385 Phase 2 Temsirolimus
20 Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients Completed NCT00458978 Phase 2 Cediranib Maleate
21 A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Terminated NCT01192815 Phase 2 erlotinib hydrochloride
22 A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN) Terminated NCT02196168 Phase 2 Cisplatin;WEE1 Inhibitor AZD1775
23 Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
24 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
25 Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
26 A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
27 A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel
28 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
29 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
30 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
31 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
32 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
33 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
34 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
35 Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study Completed NCT01254617 Phase 1 Lenalidomide
36 Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck. Active, not recruiting NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
37 A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) Terminated NCT01528137 Phase 1
38 A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer Terminated NCT00906360 Phase 1 sunitinib malate
39 A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection Terminated NCT01249443 Phase 1 vorinostat;carboplatin;paclitaxel
40 A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
41 A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer Withdrawn NCT01332279 Phase 1 everolimus;erlotinib hydrochloride
42 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
43 L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study Completed NCT01155609
44 A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System Recruiting NCT01473784
45 A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers Active, not recruiting NCT02245100
46 Outcomes in Transoral Robotic Microsurgery for Head and Neck Tumors Terminated NCT01254734
47 Prospective Evaluation of Esophageal Pathology Treatment of Head and Neck Carcinoma Terminated NCT01164566
48 Selecting for Cetuximab Responders in Advanced Head and Neck SCC Terminated NCT02177838 cisplatin

Search NIH Clinical Center for Larynx Verrucous Carcinoma

Genetic Tests for Larynx Verrucous Carcinoma

Anatomical Context for Larynx Verrucous Carcinoma

Organs/tissues related to Larynx Verrucous Carcinoma:

MalaCards : Endothelial, Lung, Breast, Brain, Liver

Publications for Larynx Verrucous Carcinoma

Articles related to Larynx Verrucous Carcinoma:

(show top 50) (show all 62)
# Title Authors PMID Year
1
Definitive Radiotherapy versus Surgery for the Treatment of Verrucous Carcinoma of the Larynx: A National Cancer Database Study. 62
35846806 2022
2
Flexible endoscopic approach to verrucous carcinoma of the larynx. 62
34473404 2021
3
Patterns of Care and Outcomes in Verrucous Carcinoma of the Larynx Treated in the Modern Era. 62
32850375 2020
4
Is primary radiotherapy an acceptable treatment modality for verrucous carcinoma of the larynx? 62
30950508 2019
5
Systemic therapy in non-conventional cancers of the larynx. 62
29909903 2018
6
Laryngeal Verrucous Carcinoma: A Population-Based Analysis. 62
26124268 2015
7
Verrucous carcinoma of the larynx presenting as a hairy lesion. 62
24823530 2014
8
[Diagnosis and management of laryngeal verrucous carcinoma (case report in one patient and literature review)]. 62
23898617 2013
9
Verrucous carcinoma of the larynx: determining the best treatment option. 62
16626921 2006
10
Pathologic quiz case: laryngeal lesion in an elderly man. Verrucous carcinoma of the larynx. 62
15628892 2005
11
[Results of the surgery in verrucous carcinoma of the larynx]. 62
10974894 2000
12
Verrucous carcinoma of the larynx. 62
9596216 1998
13
Verrucous carcinoma of the larynx: a review of 53 patients. 62
9570624 1998
14
[Unusual variant of laryngeal squamous cell carcinoma: verrucous carcinoma]. 62
9707746 1998
15
[Verrucous carcinoma of the larynx. Diagnostic and therapeutic problems]. 62
9207880 1997
16
[Verrucous carcinoma of the larynx. An analysis of 20 years of experience]. 62
9199100 1997
17
Verrucous carcinoma of the larynx presenting as a hairy whitish tumor. 62
18493443 1997
18
CO2 laser surgery for verrucous carcinoma of the larynx. 62
9261788 1997
19
Human papillomavirus and p53 oncoprotein in verrucous carcinoma of the larynx. 62
8869607 1996
20
Outcome following radiotherapy in verrucous carcinoma of the larynx. 62
7790246 1995
21
[Verrucous carcinoma of the larynx]. 62
17974455 1995
22
[Verrucous carcinoma of the larynx]. 62
7734165 1995
23
Verrucous carcinoma of the larynx. 62
7816455 1995
24
Polymerase chain reaction (PCR) identification of human papillomavirus (HPV) DNA in verrucous carcinoma of the larynx. 62
8384679 1993
25
Verrucous carcinoma of the larynx: role of human papillomavirus, radiation, and surgery. 62
8382761 1993
26
[Parakeratosis of larynx as a base of cancerogenesis]. 62
8259290 1993
27
[Controversial aspects of verrucous carcinoma of the larynx: viral etiology, diagnosis and treatment]. 62
1665071 1991
28
Management of verrucous carcinoma of the larynx. 62
2070533 1991
29
Human papillomavirus DNA sequences in cell lines derived from head and neck squamous cell carcinomas. 62
1851275 1991
30
[Verrucous carcinoma of the larynx]. 62
2631914 1989
31
[Verrucous carcinoma of the larynx]. 62
2555068 1989
32
Clinical and histopathological considerations for the diagnosis and treatment of verrucous carcinoma of the larynx. 62
2757559 1989
33
Verrucous carcinoma of the larynx. 62
3240742 1988
34
[Verrucous carcinoma of the larynx]. 62
3273562 1988
35
Verrucous carcinoma of the larynx. 62
3138618 1988
36
Late response of verrucous carcinoma of the larynx to radiotherapy. 62
3356941 1988
37
Diagnosis and management of verrucous carcinoma of the larynx. 62
3154665 1988
38
Verrucous carcinoma of the larynx: problems of diagnosis and treatment. 62
3343571 1988
39
Verrucous carcinoma of the larynx--a misnomer. 62
3662922 1987
40
[Anatomo-clinical study of 7 cases of verrucous carcinoma of the larynx]. 62
3618981 1987
41
Verrucous carcinoma (Ackerman's tumor) of the larynx: diagnostic and therapeutic considerations. 62
3623929 1986
42
Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. 62
3004723 1986
43
Verrucous carcinoma of the larynx. Possible human papillomavirus etiology. 62
2996475 1985
44
Anaplastic transformation of verrucous carcinoma following radiotherapy. 62
4083379 1985
45
[Verrucous carcinoma of the larynx]. 62
3834369 1985
46
[The first description of verrucous carcinoma of the larynx]. 62
3912702 1985
47
[Verrucous carcinoma of the larynx. Clinico-pathologic study of 15 cases]. 62
6670729 1983
48
[Verrucous carcinoma of the larynx]. 62
6218249 1982
49
Verrucous carcinoma of the larynx. 62
7172465 1982
50
[Indications for conservative surgical treatment of squamous cell verrucous carcinoma of the larynx]. 62
7348018 1981

Variations for Larynx Verrucous Carcinoma

Expression for Larynx Verrucous Carcinoma

Search GEO for disease gene expression data for Larynx Verrucous Carcinoma.

Pathways for Larynx Verrucous Carcinoma

GO Terms for Larynx Verrucous Carcinoma

Sources for Larynx Verrucous Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....